Blog
    Condition FocusFor PhysiciansAugust 13, 2026

    Melanotan II and Cartalax Evidence for Skin and Aging

    Review clinical and preclinical evidence for Melanotan II and Cartalax (AED peptide) regarding melanogenesis, receptor selectivity, and cellular aging markers.

    This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.

    1. Clinical Question

    How do the evidence profiles of Melanotan II and the tripeptide Cartalax compare regarding their efficacy and safety for skin pigmentation and anti-aging applications?

    2. Evidence Snapshot

    Melanotan II

    • Evidence Grade: C
    • Study Types: Clinical tanning confirmation; regulatory safety communications.
    • Regulatory Status: Not approved; FDA/TGA safety warnings issued.
    • Outcomes: Confirmed skin darkening (tanning); identified risks of non-selective receptor activation.

    Cartalax (AED Peptide)

    • Evidence Grade: C (Low-confidence, borderline C/D)
    • Study Types: Single small human study (unregistered, embedded in patent); preclinical animal and cell models.
    • Sample Size: 29 human subjects (knee OA study); various preclinical models (rat, MSCs).
    • Outcomes: Improved pain/mobility in OA subjects (54.5–62.7%); no radiographic improvement; modulation of aging markers in preclinical models.

    3. What the Research Shows

    Melanotan II The evidence confirms that Melanotan II functions as a skin-darkening agent through the stimulation of melanogenesis. Research indicates that the compound achieves this by acting as a non-selective agonist across multiple melanocortin receptors (MC1R through MC5R). While its primary observed clinical effect is tanning, clinical concerns have been raised regarding its potential for melanoma promotion. Due to its non-selective nature, it produces various off-target effects beyond skin pigmentation.

    Cartalax Human evidence for Cartalax is limited to a single study of 29 patients with knee osteoarthritis, detailed within patent documentation. In this group, 54.5% to 62.7% of subjects reported improvements in pain and mobility after receiving intramuscular doses (1 µg to 5 mg) daily for 20 days. However, no radiographic improvements were observed, and the study lacked p-values and an adverse event (AE) table.

    In the context of aging and skin, evidence is primarily preclinical. Cartalax has been studied in skin aging models and old-rat nephroprotection models. Preclinical data shows it may influence cartilage explants and stimulate chondrocyte proliferation (1.4–2.1x at 200 ng/mL). Its role in aging is linked to the modulation of specific genetic markers in cell cultures.

    4. Mechanism

    Melanotan II Melanotan II is a non-selective melanocortin receptor agonist. It targets MC1R through MC5R. The stimulation of MC1R is responsible for melanogenesis (skin darkening). However, its non-selectivity leads to the activation of other pathways:

    • MC3R/MC4R: Activation affects appetite and sexual function.
    • MC5R: Activation affects sebaceous glands.

    Cartalax Cartalax is a tripeptide (Ala-Glu-Asp) with a molecular weight of 333.29 g/mol. It is proposed to normalize bone and cartilage metabolism. The mechanism involves the modulation of chondrocyte gene expression, specifically targeting:

    • Structural markers: SOX9, aggrecan, type II collagen, and COMP.
    • Aging-related markers: SIRT1, SIRT6, Ki-67, and p53.

    5. Limitations of the Evidence

    Melanotan II The primary limitation of Melanotan II is its non-selective receptor activation, which causes multiple off-target effects. There are significant safety concerns highlighted by regulatory bodies, including the FDA and TGA, specifically regarding melanoma promotion. It lacks regulatory approval for clinical use.

    Cartalax The evidence for Cartalax is categorized as low-confidence (Grade C/D). There are no registered clinical trials, no Phase III data, and no approval from the FDA or EMA. Human data is restricted to a single patent-embedded narrative that is difficult to audit and contains inconsistencies regarding dose rationale. The study lacked statistical rigor, missing both p-values and a standardized adverse event table. Much of the data regarding aging is confined to preclinical animal or MSC models.

    6. Clinical Takeaway

    Melanotan II has confirmed efficacy for skin darkening but is limited by non-selective receptor activity and significant safety warnings from international regulatory agencies. Cartalax (AED peptide) shows potential in preclinical models for modulating aging-related markers and has limited, low-confidence human data regarding joint mobility, but lacks robust clinical trial evidence or regulatory clearance for anti-aging or skin health. Both compounds currently lack the necessary clinical validation and safety profile for standard medical use.

    7. Sources

    • Melanotan II: University of Arizona development records; FDA Safety Communications; TGA Safety Communications.
    • Cartalax: Patent RU2299741C1 / WO2007139433A1 / EA010574B1 (Khavinson group); Dietary supplement certification RU.77.99.88.003.R.004070.11.22.

    Referenced Peptides

    melanotan iicartalax

    This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.